Immunotherapy for Unresectable Stage III Non–Small-Cell Lung Cancer

In this issue of the Journal, Antonia and colleagues report the results of the phase 3 PACIFIC study, which evaluated the role of immune checkpoint blockade in locally advanced, unresectable, stage III non–small-cell lung cancer (NSCLC).1 Eligible patients had disease that had not yet progressed after they had received at least two cycles of platinum-based chemotherapy concurrent with radiotherapy (chemoradiotherapy) at a dose of 54 to 66 Gy. A total of 713 patients were randomly assigned, in a 2:1 ratio, to receive an anti–programmed death ligand 1 (anti–PD-L1) antibody, durvalumab, at a dose of 10 mg per kilogram of body . . .